Solid Solution Compositions and Use in Chronic Inflammation
US-2015342880-A1 · Dec 3, 2015 · US
Use of artemether in the prevention and treatment of Alzheimer's disease
US12453715B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12453715-B2 |
| Application number | US-202117206420-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 19, 2021 |
| Priority date | Oct 8, 2018 |
| Publication date | Oct 28, 2025 |
| Grant date | Oct 28, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of diseases related to insufficiency of AMPK phosphorylation and GSK-3β (ser9) phosphorylation in a subject in need thereof, comprising: administering artemether to the subject; wherein the diseases related to insufficiency of AMPK phosphorylation and GSK-3β (ser9) phosphorylation comprise one or more selected from the group consisting of pulmonary infectious diseases and pulmonary fibrosis, and the dosage of artemether is about 0.1 mg/kg body weight/day to about 20 mg/kg body weight/day. 2. The method of claim 1 , wherein said method further comprises: detecting a patient with insufficiency of AMPK phosphorylation and GSK-3β (ser9) phosphorylation. 3. The method of claim 1 , wherein said artemether is administered at least once per day. 4. The method of claim 1 , wherein said artemether is administered by injection or orally.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
- A61K31/357Primary
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12453715B2 cover?
- Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline ac…
- Who is the assignee on this patent?
- Univ Macau
- What technology area does this patent fall under?
- Primary CPC classification A61K31/357. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).